{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.2"},{"groupId":"OG001","value":"66.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"289"}],"units":"Participants"}],"description":"ORR defined as number of participants achieving a complete response (CR), complete response with incomplete marrow recovery (CRi), nodular partial response (nPR) or partial response (PR). IWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils \\>1.5\\*10\\^9/liter (L), platelets \\>100\\*10\\^9/L, Hgb \\>11 gram per deciliter (g/dL) and absolute lymphocyte count \\<4000/microliter (mcL); CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but the bone marrow biopsy shows B-lymphoid nodules, may represent a clonal infiltrate; PR-2 of the following when abnormal at baseline: \\>=50% decrease in ALC, \\>=50% decrease in sum products of up to 6 lymph nodes, \\>=50% decrease in enlargement of spleen or liver; and 1 of the following: neutrophils \\>1.5\\*10\\^9/L, Platelets \\>100\\*10\\^9/L and Hgb\\>11 g/dL or \\>=50% improvement over baseline in any of these; no new enlarged nodes or new hepatosplenomegaly.","groups":[{"description":"Participants received ibrutinib 420 milligram (mg) (3 \\* 140 mg capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles ibrutinib alone was administered until disease progression or unacceptable toxicity.","id":"OG000","title":"Ibrutinib+BR"},{"description":"Participants received placebo (3 capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles placebo alone was administered until disease progression or unacceptable toxicity.","id":"OG001","title":"Placebo+BR"}],"paramType":"NUMBER","populationDescription":"Intent to treat (ITT) population included all participants randomized into the study regardless of treatment actually received.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}